Richard Lehman’s journal review – 23 January 2012
Latest BMJ blogs,
JAMA 18 Jan 2012 Vol…
JAMA 18 Jan 2012 Vol…
You may well recall the excitement around the late-stage clinical data for Zelboraf (vermurafenib, PLX4032) in metastatic…
The BRAF inhibitor vemurafenib prolongs progression-free survival and overall survival in patients with BRAF-mutant melanoma.